Key result
Spironolactone co-treatment significantly attenuated isoproterenol-induced increases in left ventricular end-diastolic pressure (3.0 vs 7.8 mmHg), myocardial fibrosis, and MMP-2 expression in rats.
Why the study?
Does spironolactone reduce isoproterenol-induced ventricular fibrosis and MMP-2 expression in rats?
Does spironolactone reduce isoproterenol-induced ventricular fibrosis and MMP-2 expression in rats?
Spironolactone attenuates isoproterenol-induced left ventricular fibrosis and MMP-2 activation in rats, suggesting the mineralocorticoid receptor system mediates sympathetic hyperactivity-induced cardiac remodeling.
Answers are grounded in this paper and cite their sources.
Spironolactone attenuates ISO-induced fibrosis and MMP-2 in rats; leaves open mineralocorticoid mediation of sympathetic cardiac remodeling in humans.
Although transregulation between the sympathetic nervous system and the renin-angiotensin-aldosterone system has been reported, it remains unclear whether sympathetic hyperactivity-induced matrix metalloproteinease (MMP) expression/activity and cardiac fibrosis are mediated by the mineralocorticoid receptor system. We investigated whether isoproterenol (ISO)-induced MMP expression/activity and cardiac fibrosis are mediated by spironolactone in rats. Male Wistar Kyoto rats were divided into 3 groups: control, ISO, and ISO combined with spironolactone (SPI). ISO (2.0 mg/kg/d) and/or SPI (40 mg/kg/d) were given for 14 d. Echocardiography and hemodynamic measurements were recorded and hearts were excised. The myocyte cross-sectional and fibrotic area was evaluated via histopathological analysis. MMP-2 and collagen-I were analyzed by Western blotting and zymography. Compared with the controls, ISO significantly elevated the end-diastolic left ventricular (LV) pressure and the time constant of isovolumic relaxation and decreased the -dP/dt, while those of SPI co-treatment did not. ISO treatment induced significant increases in the fractional shortening and relative wall thickness, whereas SPI co-treatment significantly decreased relative wall thickness. Similarly, ISO significantly increased LV weight and myocyte cross-sectional and fibrotic area, which occurred concomitantly with the MMP-2 expression/activity and the expression of collagen-I. Moreover, ISO induced these features were significantly attenuated by SPI co-treatment. Our results suggest that ISO-evoked sympathetic hyperactivity induced LV fibrosis and MMP-2, which may be partially controlled via the mineralocorticoid receptor system.
No takes yet. Share an insight, caveat, or question.
Hori et al. (2011) studied Isoproterenol-induced ventricular fibrosis and cardiac hypertrophy (n=27). Spironolactone vs. Isoproterenol alone (2.0 mg/kg/d) was evaluated on Left ventricular end-diastolic pressure (LVEDP) (p=<0.01). Spironolactone co-treatment significantly attenuated isoproterenol-induced increases in left ventricular end-diastolic pressure (3.0 vs 7.8 mmHg), myocardial fibrosis, and MMP-2 expression in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: